GlassScriptPhysician profile
Aaron Cohn
NPI 1841586211
$8,253.13
in general payments reported to CMS, 2019-2025
11 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $21.22 · 2021: $32.50 · 2022: $408 · 2023: $6,462 · 2024: $537 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,288 · Food and Beverage: $1,297 · Education: $85.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,287.50 |
| Food and Beverage | $1,296.96 |
| Education | $85.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $4,447.75 | 2022-2025 | Rebyota |
| Abbvie INC. | $2,414.52 | 2021-2025 | Viberzi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $585.35 | 2024-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $135.64 | 2025 | Omvoh |
| Ardelyx, INC. | $135.27 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2022 | |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Boston Scientific Corporation | $121.24 | 2019 | |
| Genzyme Corporation | $60.88 | 2022 | |
| Medtronic, INC. | $56.00 | 2023 | Gi Genius |
| Takeda Pharmaceuticals U.S.A., INC. | $46.49 | 2020-2023 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Cohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.